about
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell TransplantationAACR Cancer Progress Report 2014Use of patient registries and administrative datasets for the study of pediatric cancerParticipating in research: attitudes within the African American church.The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendationsEmerging uses of patient generated health data in clinical research.Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology GroupUsing electronic medical record data to report laboratory adverse events.Impact of primary care provider knowledge, attitudes, and beliefs about cancer clinical trials: implications for referral, education and advocacy.Resolving Rivalries and Realigning Goals: Challenges of Clinical and Research Multiteam Systems.The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.Promoting Factors and Barriers to Participation in Early Phase Clinical Trials: Patients Perspectives.An overview of EMPaCT and fundamental issues affecting minority participation in cancer clinical trials: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual.Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer.Expanding public-private collaborations to enhance cancer drug development: a report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century"Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plansA disparity of words: racial differences in oncologist-patient communication about clinical trialsAutomated determination of metastases in unstructured radiology reports for eligibility screening in oncology clinical trialsCreating a "culture of research" in a community hospital: Strategies and tools from the National Cancer Institute Community Cancer Centers ProgramKRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practiceTumor board participation among physicians caring for patients with lung or colorectal cancer.An adverse event capture and management system for cancer studiesPatient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study.The bottleneck effect in lung cancer clinical trials.Stakeholder participation in comparative effectiveness research: defining a framework for effective engagementAssessing the impact of a cooperative group trial on breast cancer care in the medicare population.The Children's Oncology Group's 2013 five year blueprint for researchEffect of state-mandated insurance coverage on accrual to community cancer clinical trials.Culturally Competent Strategies for Recruitment and Retention of African American Populations into Clinical TrialsOrganizational designs for achieving high treatment trial enrollment: a fuzzy-set analysis of the community clinical oncology program.Improving the outcome for children with cancer: Development of targeted new agents.Enrollment and Racial Disparities in Cancer Treatment Clinical Trials in North Carolina.Current Status and Challenges of Cancer Clinical Trials in KoreaSurvival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy erasEnrollment of patients with lung and colorectal cancers onto clinical trials.Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment.Optimizing Enrollment of Patients into Nephrology Research Studies.Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity ProgramImproved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma centerAccuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.
P2860
Q26740251-A057D9E6-4A8C-4391-B87B-49FB8D517223Q27346723-8B24BF33-490E-40BC-A64B-06D03E94872CQ28087326-D82FC580-05DE-42C6-848B-3D5F0E4B8E3CQ30224492-FBC2F7A7-F705-42ED-A904-69B556E73007Q30557206-A801C720-9760-4389-AB74-86A56139F4E1Q30854718-ADECAD35-55AC-4214-9AD5-2D632B56B9E7Q31028140-0D12CFDD-5FBA-4110-8A0E-57229F448688Q31158675-1CE2A399-0867-4BCA-8419-BD2E4F7A67CBQ33637104-D7837DEA-F742-4BA6-9402-8956D0F5C3D7Q33756587-0AD35B1F-BF76-48F8-9DCF-A0B3E96E9D2EQ33865329-FCC260A1-5ACD-4E68-839A-CA451A109DCDQ33956979-04264C48-D0D6-4B8B-9784-16CE47A03859Q34049831-AC00B40E-43AA-4E2D-99F7-88CC0B49501EQ34209081-64C84AD2-80D6-47EF-B35D-F29A64D3F206Q34458056-FB7B6D90-FD0A-43A1-8DC0-0308BA742FC8Q34488734-20C5D361-AAE1-4DBA-9C4F-49788B7AF323Q34890136-EA87C44C-4803-4DE1-93E9-362DAF8CDDBEQ35174686-34445FF0-0B94-4358-98BC-E2CABBD545C7Q35572502-FBAA1958-D961-4111-91C6-29468325FAC5Q35584667-E1C153A1-A2C0-4509-9D20-6BDB0A5381ACQ35625674-76179B43-6E76-4BF2-A0FD-EB602A226A5BQ35794404-EB7ECD14-E297-442E-A2B2-FC8BE0AF55FDQ35810590-8F19E8DE-77F3-4A64-B909-743B557AD4B6Q35850218-756793CD-579A-4A4E-9C6B-F873CDE12243Q36021512-87870968-6349-4812-9C7A-393044F69D1BQ36058251-9E4B4C2F-3D4F-4F72-ABA0-9813B67ADE22Q36087865-84A866DF-1C75-439A-B13F-DE640F75D810Q36129425-4FDD686F-10A4-47C8-B804-E4030ACAD16DQ36225685-C1F2C0F6-2ED2-4BA4-BBCF-C28660CE6E68Q36226295-7E680558-E39D-4F54-9EEC-9E60FBD83B1BQ36238795-C5B2A44B-4CFD-41CF-A36B-5028AC03D3E9Q36467761-8D1A1B69-F29C-4E00-A52A-A999146796B9Q36482459-B4B70447-2CF7-4B9C-A2F0-9A4B72289C11Q36528402-EDE8CEAB-44E2-4FCE-B452-B4E812CD825AQ36678225-1BFFA72C-2FBA-47C1-B4B0-D687A9FB2F4BQ36678241-8DD4AFE5-1B20-4D95-BD8F-6B2794C485FBQ36687007-2BA0D192-8D2D-41D6-AAB9-A09274FE9A7CQ36788307-8722FE5E-4CAC-4164-8FE3-5242A24990C3Q36883521-DC403D7E-9149-4059-8FF0-F7E0B069F32AQ36915159-A11B1DA2-7FD4-4A05-A058-A4A153D0EA21
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
type
altLabel
A National Cancer Clinical Trials System for the 21st Century
@en
P3181
P356
P1433
P1476
A National Cancer Clinical Trials System for the 21st Century
@en
P3181
P356
10.17226/12879
P407
P577
2010-01-01T00:00:00Z